Nevertheless, anti-tumor activity of 5-azadC has been reported in BC patients with a response rate of up to 50% and, more recently, levels of DNMT proteins have been proposed as biomarkers for decitabine response in TN BC [28, 60]. The gene discussed is DNMT1; the disease is breast cancer.